May I add to that?
Monsieur Gagnon is talking on the biotech side. On the pharmaceutical side, where we are looking at the SR and ED tax credit, we're looking at the definition and whether the definition could be consistent with the OECD definition, which is to expand it to include the social sciences. That's so projects, pharmaco-economics, different health care management programs--because we have a lot of universities developing those programs now--disease management programs that companies run can also be included in terms of your tax credit, which is less than $60 million a year.
So there are two different components, one that could target pharmaceuticals and one that could target biotech specifically.